Pancreatic Adenosquamous Carcinoma
Associated Genetic Biomarkers
NCI Definition: A carcinoma that arises from the pancreas showing both ductal and squamous differentiation. The squamous component should represent at least 30% of the malignant cellular infiltrate. The prognosis is usually worse than that of ductal adenocarcinoma. 
Pancreatic adenosquamous carcinomas most frequently harbor alterations in KRAS, TP53, CDKN2A, SMAD4, and CDKN2B .
KRAS Mutation, KRAS Exon 2 Mutation, KRAS Codon 12 Missense, TP53 Mutation, and KRAS G12D are the most common alterations in pancreatic adenosquamous carcinoma .
There are 7 clinical trials for pancreatic adenosquamous carcinoma, of which 6 are open and 1 is completed or closed. Of the trials that contain pancreatic adenosquamous carcinoma as an inclusion criterion, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 4 are phase 2 (4 open).
ATM, ATR, and BARD1 are the most frequent gene inclusion criteria for pancreatic adenosquamous carcinoma clinical trials .
Gemcitabine, nab-paclitaxel, and chemotherapy are the most common interventions in pancreatic adenosquamous carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.